22 Rue Garnier
Neuilly Sur Seine
191 articles about Servier
The oncology company added a fifth indication for its isocitrate dehydrogenase 1 inhibitor, securing the greenlight for treating patients with IDH1-mutated relapsed or refractory myelodysplastic syndromes.
Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress
Servier today announced updated data from the Phase 1 trial of TIBSOVO® (ivosidenib tablets) as monotherapy for patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
Servier presented results from the pivotal Phase 3 INDIGO clinical trial investigating vorasidenib, an investigational, oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1/2 enzymes in patients with residual or recurrent isocitrate dehydrogenase 1 or 2 mutant low-grade glioma who have been treated with surgery only.
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will showcase new data across its robust oncology portfolio at the American Society of Clinical Oncology annual meeting June 2-6, 2023.
Servier, an independent global pharmaceutical group, has announced its financial results for the 2021/22 financial year and highlighted the major steps of its ongoing transformation.
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®) and bevacizumab in adults with refractory metastatic colorectal cancer (mCRC), demonstrating that the trial met its primary endpoint of overall survival (OS).
Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia
Servier announced findings from a retrospective study observing higher overall survival in adolescent and young adult newly-diagnosed acute lymphoblastic leukemia patients treated with asparaginase containing pediatric-inspired regimens versus non-pediatric-inspired regimens.
Servier presented new data at the 64th Annual Meeting of the American Society of Hematology characterizing clonal evolution and relapse mechanisms in patients with newly-diagnosed IDH1-mutated acute myeloid leukemia who are 75 years of age or older or have comorbidities that preclude use of intensive induction chemotherapy treated with TIBSOVO in combination with azacitidine.
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will present new data in acute lymphoblastic leukemia and acute myeloid leukemia at the 64th Annual Meeting of the American Society of Hematology taking place December 10–13, 2022.
Allogene Therapeutics' French partner Servier has withdrawn all involvement in the development of Allogene’s anti-CD19 products, allowing Allogene to license its CD19 products outside the U.S.
Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.
Wide range of research across tumor types underscores Servier's commitment to discovering novel approaches to addressing difficult-to-treat cancers.
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key secondary endpoints, complete remission rate, overall survival, complete remission and complete remission with partial hematologic recovery rate.
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for TIBSOVO.
Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier announced Phase 3 data demonstrating that TIBSOVO® in combination with the chemotherapy azacitidine significantly improved event-free survival and overall survival compared to azacitidine plus placebo in adults with previously untreated IDH1-mutated acute myeloid leukemia who are not candidates for intensive chemotherapy.
Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced new data in acute myeloid leukemia to be presented at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier, a global pharmaceutical company, announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO in combination with the chemotherapy azacitidine in adults with previously untreated IDH1-mutated acute myeloid leukemia met its primary endpoint of event-free survival.
Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research
- Servier today announced that Clinical Cancer Research has published data from its Phase 1 study evaluating single-agent vorasidenib in isocitrate dehydrogenase (IDH) mutant advanced solid tumors, including low-grade glioma.
Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021
Data suggest short-term treatment with vorasidenib and TIBSOVO reduces tumor cell proliferation, alters epigenetic state, and promotes expression of genes associated with cellular differentiation BOSTON , J
Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb's IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets